FDA grants Breakthrough Therapy Designation to Roche's inavolisib for advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation

The designation is based on Phase III INAVO120 results, showing the inavolisib-based regimen more than doubled progression-free survival compared with palbociclib and fulvestrant alone in the...

Related Keywords

Japan ,Switzerland ,United States ,San Antonio ,Texas ,America ,Bruno Eschli ,Sabine Borngr ,Nathalie Altermatt ,Karsten Kleine ,Sileia Urech ,Birgit Masjost ,Levi Garraway ,Rebekka Schnell ,Kirti Pandey ,Loren Kalm ,Yvette Petillon ,Simon Goldsborough ,National Cancer Institute ,Head Of Global Product Development ,Roche Group ,Drug Administration ,European Medicines Agency ,Genentech ,Wales Cancer Network ,Ends Result Program ,Breakthrough Therapy Designation ,Chief Medical Officer ,Global Product ,Therapy Designation ,European Medicines ,Dow Jones Sustainability Indices ,Chugai Pharmaceutical ,San Antonio Breast Cancer Symposium ,Systematic Review ,Diagnostic Workup ,Metastatic Breast ,Intj Breast ,Breakthrough Therapy Approvals ,Breakthrough Therapy ,Study Evaluating ,Patients With ,Hormone Receptor Positive ,Locally Advanced ,Metastatic Breast Cancer ,Participants With ,Metastatic Breast Cancer Post ,Endocrine Combination Therapy ,Combination With Phesgo Versus Placebo ,Combination With Phesgo ,Positive Locally Advanced ,Cancer Institute ,Ends Result ,Cancer Stat Facts ,Female Breast Cancer Subtypes ,Williston Park ,Adv Med ,